Key Highlights

  • Shares closed at A$193.39 on 18 November 2026, down 4.10% on the day and down approximately 23% over one year.
  • Visage Imaging signed a 7-year contract worth A$43 million with Virtua Health on 21 October 2026.
  • The contract covers a unified enterprise imaging platform to be implemented in the cloud.
  • The release describes a transaction-based licensing model with potential upside.

Pro Medicus Limited (ASX:PME) develops health imaging software through its US Subsidiary Visage Imaging. Its shares closed at A$193.39 on 18 November 2026, down 4.10% for the session and down approximately 23% over the past year. The company announced the Virtua Health contract on 21 October 2026.

Latest Update

On 21 October 2026, Pro Medicus announced that its wholly owned US subsidiary, Visage Imaging, had signed a 7-year contract worth A$43 million with Virtua Health, an academic health system based in South Jersey, New Jersey. The contract covers a unified enterprise imaging platform comprising Visage 7 Viewer, Visage 7 Workflow, Visage 7 Open Archive and Visage 7 Cardiology.

The release states that the Visage 7 platform will be implemented in the cloud and that the contract is based on a transactional licensing model. The company said the model has potential upside, depending on the Volume of activity on the platform.

Company Background and Sector Context

Virtua operates across five hospitals, with around 15,000 colleagues and 3,000 affiliated doctors and clinicians, according to the release. The health system is academically affiliated with Rowan University, Penn Medicine and the Children's Hospital of Philadelphia.

Hospital imaging software is sold on long contract terms, and providers are shifting workloads to cloud platforms. Pricing and contract structures in the sector vary, and procurement decisions are typically made over several years.

Pro Medicus sells enterprise imaging software to hospitals and health systems, primarily in the United States, where its Visage platform is used for radiology and cardiology workflows. Contracts in this area are typically multi-year and are shaped by hospital procurement cycles and cloud migration plans. The Virtua agreement is described in the release as covering a unified platform across several imaging functions, which the company said will be implemented in the cloud.

Risks and Uncertainties

The contract value depends on the transaction-based model, so Revenue will vary with usage rather than being fixed across the term. The release does not set out expected revenue phasing in the opening sections.

Concentration in US health systems and the timing of cloud implementations are factors that could affect when revenue is recognised. Competition in health imaging software can also affect pricing and renewals.

What to Watch Ahead

Investors will look for the implementation timetable for the Virtua contract, further contract announcements and the company's half-year result, which will show the contribution from new agreements.

Investors will also track the progress of other contract announcements, the number of hospitals and health systems using the platform and any changes to the transactional licensing model. Each of these will show whether the Virtua agreement is one of a growing set of contracts across the company's customer base.

Taken together, the announcement sets out a seven-year contract with a US health system on a transaction-based model, alongside a share price that has fallen over the past year. Future contract announcements and the implementation timetable will indicate how the platform develops.